AUTHORS
Manisha Bhutani, MD, Myra Robinson2, David M Foureau, MS, PhD3, Shebli Atrash, MD4, Barry Paul, MD, MS5, Mauricio Pineda-Roman6, Cindy Varga, MD7, Reed Friend, MD8, Christopher Ferreri, MD9, Xhevahire Begic10, Sarah Norek11, Shelby Clark12, Michelle B Anderson13, Fei Guo14, Jason Grayson15, Anna Ivanina-Foureau16, Lawrence J Druhan, PhD17, James T Symanowski18, Saad Z. Usmani, MD19, Peter Voorhees, MD20
AFFILIATIONS
1 Atrium Health Levine Cancer Institute, Wake Forest University School of Medicine, Charlotte, United States
2 Atrium Health Levine Cancer Institute, Charlotte, United States
3 Atrium Health Levine Cancer Institute, Charlotte, United States
4 Atrium Health Levine Cancer Institute, Wake Forest University School of Medicine, Charlotte, United States
5 Atrium Health Levine Cancer Institute, Wake Forest University School of Medicine, Charlotte, United States
6 Atrium Health Levine Cancer Institute, Wake Forest University School of Medicine, Charlotte, United States
7 Atrium Health Levine Cancer Institute, Wake Forest University School of Medicine, Charlotte, United States
8 Atrium Health Levine Cancer Institute, Wake Forest University School of Medicine, Charlotte, United States
9 Atrium Health Levine Cancer Institute, Wake Forest University School of Medicine, Charlotte, United States
10 Atrium Health Wake Forest Baptist Comprehensive Cancer Center Data Coordinating Center, Levine Cancer Institute, Charlotte, United States
11 Atrium Health Wake Forest Baptist Comprehensive Cancer Center Data Coordinating Center, Levine Cancer Institute, Charlotte, United States
12 Clinical Trials Unit, Atrium Health Levine Cancer Institute, Charlotte, United States
13 Atrium Health Levine Cancer Institute, Charlotte, United States
14 Atrium Health Levine Cancer Institute, Charlotte, United States
15 Wake Forest University School of Medicine, Winston-Salem, United States
16 Atrium Health Levine Cancer Institute, Charlotte, United States
17 Hematology Oncology Translational Research Laboratory, Atrium Health Levine Cancer Institute, Charlotte, United States
18 Atrium Health Levine Cancer Institute, Charlotte, United States
19 Memorial Sloan Kettering Cancer Center, New York, United States
20 Atrium Health Levine Cancer Institute, Wake Forest University School of Medicine, Charlotte, United States
ABSTRACT
Background: We previously reported results of a phase 2 trial evaluating daratumumab, carfilzomib, lenalidomide (len), and dexamethasone (Dara-KRd) induction followed by a next-generation sequencing (NGS)-based measurable residual disease (MRD)-adapted post-induction strategy in newly diagnosed multiple myeloma (NDMM). At a median follow-up of 30.1 months, Dara-KRd previously demonstrated high rates of deep response and MRD negativity. Here, we report extended follow-up with updated survival outcomes, durability of MRD-negative status, and patterns of progression.
Methods: Thirty-nine patients with NDMM were enrolled and initiated Dara-KRd induction (planned 8 cycles of 28 days each). Three patients did not reach post-induction group assignment. Of the remaining 36, patients were assigned by post-induction MRD status by NGS (10⁻⁵): MRD-negative patients (Group A, n=24) received len maintenance; MRD-positive transplant-eligible patients (Group B, n=8) underwent ASCT followed by len maintenance; and MRD-positive transplant-ineligible patients (Group C, n=4) received KRd consolidation followed by len maintenance. MRD was assessed by both NGS (clonoSEQ) and next-generation flow cytometry (NGF) at protocol-defined timepoints. Duration of MRD negativity was evaluated using Kaplan-Meier methods, calculated from first MRD-negative result to first MRD-positive result (event) or censored at last negative assessment. Data cutoff was April 29, 2026.
Results: At a median follow-up of 56.3 months (range: 1.7–74.5, n=39), best overall MRD-negative rates by NGS were 79.5% (10⁻⁵) and 71.8% (10⁻⁶), and 87.2% (10⁻⁵) and 74.4% (10⁻⁶) by NGF. The rate of ≥CR with MRD negativity by NGS was 64.1% (10⁻⁵) and 61.5% (10⁻⁶). Among Group A patients achieving MRD negativity, sustained MRD negativity rates at 10⁻5 sensitivity from first negative assessment by NGS were 89.6% at 24 months and 72.4% at 36 months; by NGF, rates were 90.2% and 85.2%, respectively. At 10⁻⁶ sensitivity, sustained MRD negativity by NGS was 84.8% at 24 months and 67.4% at 36 months; by NGF, rates were 89.7% and 84.4%, respectively. Among 6 patients with MRD resurgence by NGS (10⁻⁵) in Group A, 5 developed IMWG progression: 2 had simultaneous MRD positivity and progression, while 3 progressed at 2, 7, and 8.3 months after first MRD positivity. Among 4 patients with MRD resurgence by NGF (10⁻⁵) in Group A, all 4 developed IMWG progression: 2 had simultaneous MRD positivity and progression, while 2 progressed at 2 and 8.3 months after first MRD positivity. Discordance between NGS and NGF was observed: one patient remained concordantly MRD-negative by both methods for 48 months before converting to MRD-positive by NGS, followed by IMWG progression 7 months later. Overall, the estimated 4-year PFS was 68.1% (95% CI, 49.8%–80.9%) and 4-year OS was 92.2% (95% CI, 77.6%–97.4%). By group, 4-year PFS was 69.7% for Group A and 71.4% for Group B. A total of 13 patients progressed or died (Group A: 8; Group B: 2; Group C: 1; not assigned to post-induction Group:2). No significant difference in 4-year PFS was observed between those with HRCAs (including 1q21 gain/amplification) and standard-risk cytogenetics (64.3% vs 70.6%; HR 1.39, 95% CI 0.47–4.14; n=15 vs n=24). As of data cutoff, 13 patients (33.3%) remain on protocol therapy; the median duration of lenalidomide maintenance in Group A was 37.7 months (range, 4.6–66.0). No new safety signals were identified, and no second primary malignancies were observed.
Conclusions: With extended follow-up of 56.3 months, Dara-KRd induction followed by a response-adaptive post-induction strategy demonstrates durable disease control, with 4-year OS of 92.2% and no second primary malignancies. Sustained MRD negativity at 36 months was 72.4% by NGS and 85.2% by NGF (10⁻⁵) in Group A, underscoring the depth and durability of responses achieved with this regimen. Discordance between NGS and NGF highlights the complementary value of multimodal MRD assessment, and serial MRD monitoring identified patients at risk for clinical progression, suggesting a potential window for preemptive intervention. This trial is registered on ClinicalTrials.gov (NCT04113018).
DISCLOSURES
Manisha Bhutani, MD: Johnson & Johnson - Research Funding; Takeda - Research Funding; Abbvie - Research Funding; Caribou Biosciences - Research Funding; The Binding Site - Research Funding; Celgene - Research Funding; Amgen - Research Funding; Bristol Myers Squibb - Research Funding; Caribou Biosciences - Consultancy (Includes expert testimony)